Nearly 12% of Americans have used GLP-1 weight loss drugs
Nearly 12% of Americans have used GLP-1 drugs for weight loss, including about one-fifth of women aged 50 to 64, according to a new RAND report. Surveying a… read more.
Nearly 12% of Americans have used GLP-1 drugs for weight loss, including about one-fifth of women aged 50 to 64, according to a new RAND report. Surveying a… read more.
Use of the diabetes drug metformin appears to be linked to reduced risk of dementia and death in obese patients, researchers reported on August 6, 2025 in Diabetes,… read more.
Medical tourism for bariatric and weight reduction surgery needs urgent regulation to protect recipients’ health, especially as the data show that tourist numbers are increasing despite the advent… read more.
What if we could prevent people from developing obesity? The World Obesity Federation expects more than half the global population to develop overweight or obesity by 2035. However,… read more.
Anti-obesity medications can significantly raise testosterone levels and improve health outcomes for men with obesity or type 2 diabetes, according to a new study being presented Monday at… read more.
Obesity and type 2 diabetes in adolescence can interfere with bone development, potentially increasing the risk of fractures and osteoporosis later in life, according to a study being… read more.
Simultaneous treatment with tirzepatide and menopause hormone therapy results in greater weight loss in postmenopausal women who are overweight or obese than tirzepatide monotherapy, researchers reported on July… read more.
Self-esteem scores more than doubled within one year of weight-loss surgery, according to a new study* presented today at the American Society for Metabolic and Bariatric Surgery (ASMBS)… read more.
The American College of Cardiology has issued a Concise Clinical Guidance (CCG) document to aid clinicians in the use of medication for weight management in patients where treatment… read more.
Few of the more than 90 million Americans with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment In… read more.
Biomea Fusion, a clinical-stage diabetes and obesity medicines company, announced the presentation of new preclinical and clinical data for icovamenib, the company’s investigational oral menin inhibitor, at the… read more.
Researchers report that investigative ecnoglutide is a safe and effective treatment for weight management in individuals who are overweight or obese and who do not have diabetes. The… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.